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ABSTRACT

Since its emergence in the early 1980’s HIV has killed approximately 32 million people,
and continues to kill over half a million people every year. Significant research into potential
vaccines and cures for HIV has been ongoing for decades but has been largely unsuccessful. One
of the more promising technologies that is being investigated to develop an HIV vaccine is
recombinant vaccine technology. The study presented in this thesis aims to use simian varicella
virus (SVV) and simian immunodeficiency virus (SIV) to act as a model for recombinant vaccine
development. If a recombinant SVV-SIV vaccine can be proven safe and effective at preventing
SIV in monkeys, it could provide data to aid in the development of a potential HIV vaccine for
humans. Specifically, it could aid in the development of a recombinant varicella zoster virus
expressing human immunodeficiency virus antigens (rVZV-HIV).
In this thesis, sera from rhesus macaques that were immunized with a rSVV-SIV vaccine
are analyzed. Antibody titers against SVV were determined using an indirect ELISA assay. The
goal of this thesis is to evaluate the humoral response against the SVV vector in rSVV-SIV
immunized rhesus macaques.
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Chapter 1: Background on HIV/AIDS
Emergence
In the early 1980’s doctors in the United States started to notice a peculiar rise in rare
cancers and opportunistic infections among young, homosexual men. The cause of these
infections was unknown, but patients had very low levels of CD-4 lymphocytes and once they
were symptomatic, death was almost certain. Scientists found that serum from HTLV-1, a known
retrovirus that attacked CD-4 lymphocytes, infected patients weakly stained cells from AIDS
patients, and suspected that the cause of AIDS could be another retrovirus. This theory would
prove to be true in 1983 when scientists at the Pasteur Institute isolated retroviral particles from
sera of AIDS patients. This virus, which would later prove to the be the cause of AIDS, became
known as the human immunodeficiency virus (Greene, 2007).
Simian immunodeficiency virus, SIV, is HIV’s closest relative and is endemic to many of
Africa’s native primate populations. It is believed that there have been many cross-species
transmission events of SIV viruses to humans. Most of these transmissions resulted in viruses
with limited transmissibility, but one in particular, HIV-1 group M, has become the main cause
of the AIDS epidemic (Sharp & Hahn, 2011). In 1986, three years after HIV was first isolated, a
second morphologically similar but antigenically distinct virus was discovered in humans. This
second virus was named HIV-2 and is believed to have arisen from a separate cross-species
interaction with a sooty mangabey monkey somewhere in Guinea-Bissau (Lemey et al., 2003).
Concerns that further cross-species interactions could lead to new and more dangerous HIV
viruses are valid and motivate continued research into how such interactions can be limited.
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Transmission
HIV is transmitted through bodily fluids such as blood, semen, and breast milk. Common
routes of transmission are sexual contact across mucosal surfaces, mother-infant exposure, and
percutaneous inoculation (Shaw, 2012). Contaminated blood products can also transmit HIV,
although rigorous protocols and testing have made this route of transmission rare in developed
nations. HIV infections across mucosal membranes are aided by micro abrasions or other defects
and can infect Langerhans cells, dendritic cells, or CD4 lymphocytes at the point of infection
(Shaw, 2012).
HIV mutates very quickly and as a result, when someone is exposed to HIV they are
often exposed to many genetic variants. There are many cofactors that can affect the
transmissibility of HIV. Studies have shown increased transmissibility in people who have STI’s,
are uncircumcised, or are engaged in particularly risky sexual behavior (Powers, 2008). If an
individual is known to be HIV positive and has a long-time partner who is HIV negative,
measures can be taken to lower the risk of transmission to the partner. Antiretroviral therapy can
be taken by the HIV+ individual to lower viral load, condoms can be used to control exposure,
and the HIV negative partner can take pre-exposure prophylaxis medication. When combined
these methods have been found very effective at controlling HIV transmission (Haberer et al.,
2015).

HIV Structure and Replication
HIV is an enveloped, diploid, single-stranded positive-sense RNA virus. Mature virions
are roughly spherical in shape with trimers of the gp120 glycoprotein embedded in the envelope.
Gp120 glycoproteins are anchored to the membrane by the gp41 protein. Inside of the envelope
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is a bullet shaped capsid formed from repeating units of the p24 protein. The capsid protects the
two copies of the viral genome. Also contained in each virion is a reverse transcriptase which the
virus uses to convert its vRNA into DNA that can then be integrated into the host cell genome to
establish the proviral phase.

Figure 1: HIV viral structure and viral entry via gp120 interactions with cellular
CD4 receptors (Sanders, 2012).

HIV entry into the host cell is dependent on gp120 glycoproteins interactions with host
cell CD4 receptors. These CD4 receptors are present on many cells in the immune system, but
are most prevalent on CD4+ T lymphocytes. Binding of the gp120 glycoprotein trimer to three
cellular CD4 receptors induces a conformational change in the gp120 glycoproteins that enable
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interactions with coreceptors. These coreceptors induce conformational changes in the gp41
protein and subsequent fusion of the viral envelope with the host cell membrane (Claeys &
Vermeire, 2019). After the fusion of the membranes, the capsid is released into the cytoplasm
and the reverse transcriptase begins to transcribe the vRNA into DNA that is then inserted into
the host genome. Once this is complete the vRNA is degraded and the virus replicates using the
host cell’s machinery.

Disease Progression
After exposure it usually takes a few weeks before the onset of symptoms. In the first
stage of infection, known as the acute infection period, levels of CD4+ T cells drop and viral
load increases sharply. This stage of infection is often associated with fever, chills, rash, fatigue,
and general malaise. The symptoms from the acute stage of HIV are difficult to distinguish from
other illnesses such as the flu or common cold. The length of time of the acute stage varies, but is
generally between 2-10 weeks (Hernandez-Vargas et al., 2013). After the acute stage of
infection, CD4+ T cell counts recover to near-normal levels and viral load decreases
dramatically. During this latent period infected individuals are asymptomatic, although HIV
continues to replicate and infect new cells. Because people often do not know when they are
exposed to HIV and the symptoms are easily explained by other illnesses, it is common for
individuals in the latent stage to not know they are infected. This is particularly worrisome
because although they are not symptomatic, individuals in the latent stage can still spread HIV.
The latent stage usually lasts 7-10 years, but can vary significantly between individuals.
Following the latent stage, viral loads rise rapidly while CD4+ T cell counts drop. Once CD4+ T
cells drop below 200cells/mm3 the individual is said to have acquired immunodeficiency
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syndrome, also known as AIDS. AIDS is characterized by an increase in opportunistic infections
by pathogens that a healthy individual would usually defeat. Because of their weakened immune
system, illnesses like the flu or common cold can quickly turn deadly. It is also common for
AIDS patients to develop rare malignancies such as Kaposi’s Sarcoma. Ultimately AIDS kills
individuals not because of the underlying HIV infection, but the compounding illnesses
associated with an insufficient immune system.

Diagnosis
When transmitted through mucosal tissues, HIV typically takes 7-21 days before it is
detectable in the blood. This eclipse period results from the amount of time it takes for a
sufficient number of viral particles to replicate and enter the bloodstream before they reach
detectable levels. The most common way to test for HIV infections is through rapid antibody
detection. Rapid antibody tests can give results in as little as 30 minutes, making them
convenient for clinical use. Rapid HIV tests are treated as a screening test, not a final diagnosis,
because false positives are possible, though rare. If an individual test positive on a rapid test this
is called a “preliminary positive” which can then be confirmed by either Western Blot or
immunofluorescent assays (Greenwald et al., 2006). If an individual tests positive on a rapid test
but negative on a confirmatory test, follow up testing is advised at around 4 weeks.

Treatment
When HIV first emerged in the 1980’s there were no cures, vaccines, or therapies to help
treat AIDS patients. Four decades later and with countless hours and billions of dollars poured
into research, there is still no cure or vaccine, but effective therapies to help people live longer
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lives with HIV have been developed. The current standard for HIV treatment is high activity
antiretroviral therapy (HAART). HAART works by combining antiretroviral drugs of different
classes to make it very difficult for the virus to replicate and infect new cells (Gange et al.,
2002). Early attempts to treat HIV focused on similar methods, but instead of using multiple
antiretroviral drugs, patients were only given one. This approach works for the most viral
infections, but it was not effective at treating HIV. HIV has a very high mutation rate and given
enough time was often able to develop resistance to a single drug. HAART solves this problem
because the multiple methods of inhibition make it much more difficult for the virus to mutate
around. The downside to HAART is that it does not cure the underlying HIV infection and must
be taken for the rest of one’s life. HAART does a great job of lowering viral loads in the blood,
but it cannot kill cells that are latently infected. While HAART has proven very effective there is
still a need for other treatments and for a vaccine to fully eliminate HIV. Further research into
these areas is promising with head of the United States National Institute of Allergy and
Infectious Diseases Anthony Fauci saying, “With collective and resolute action now and a
steadfast commitment for years to come, an AIDS-free generation is indeed within reach” (Fauci,
2012).
The persistence of HIV in its proviral stage is one of the biggest barriers to creating
effective cures. The size and scope of these viral reservoirs is not fully understood, but research
from John’s Hopkins suggest that HIV infected cells can replicate without releasing infectious
virus and then release virus upon subsequent stimulation (Hosmane et al., 2017).
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CHAPTER 2: BACKGROUND ON VACCINES

HIV Vaccines
Vaccine studies cannot be done on humans until they have first been tested in animal
models. Some common animal models are mouse, feline, rabbit, pig, and non-human primate
(Kiros et al., 2012). For this project non-human primate models were used to test the efficacy of
an experimental vaccine. The ultimate goal of this project is to develop a recombinant varicellazoster virus vaccine (rVZV) that can induce immunity to multiple HIV proteins. The simian
model is ideal for this project because non-human primates are susceptible to simian varicella
virus (SVV) and simian immunodeficiency virus (SIV) which are closely related to varicellazoster virus (VZV) and human immunodeficiency virus (HIV) respectively. The immediate goal
then is to create a recombinant simian varicella virus vaccine that can also induce immunity to
simian immunodeficiency virus (SIV). To understand the advantages of the simian model, a
discussion of the similarities between VZV and SVV, as well as HIV and SIV is included below.
As discussed earlier in this paper, HIV originated from cross species interactions with
primates infected with SIV. It follows then that the viruses are very similar in their structure,
function, and mode of infection. Both SIV and HIV are retroviruses with RNA genomes that
infect the host and cause latent infections. After the latent period, both viruses destroy the host
immune system and ultimately lead to death. Both viruses attack CD4+ cells of the immune
system and both viruses have similar pathophysiology which include a decline in the number of
CD4+ T cells, neurologic abnormalities, and opportunistic infections (Fauci, 1997).
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SVV and VZV are also very closely related. They share 75% DNA homology, are both
alpha-herpesviruses, and share immunological cross reactivity (Nicholas, 2011). Both viruses
produce varicella, an acute and highly contagious disease characterized by small, itchy blisters;
fever; and malaise. SVV and VZV can both sit latent in ganglionic neurons and become
reactivated by environmental stressors to produce zoster. In humans, acute illness associated with
VZV infection is referred to as chickenpox. While VZV was once very common, the introduction
of the VZV Oka vaccine in 1995 has led to a dramatic drop in chickenpox and has proven to be a
safe and effective vaccine. Because the VZV vaccine is a live attenuated vaccine, it presents the
opportunity for researchers to add foreign genetic material into the VZV genome. There are
many advantages to using VZV vectors to introduce foreign antigens. VZV has a large genome
with dispensable regions which allow the introduction of multiple foreign genes, VZV is known
to be able to induce a strong immune response, and the VZV Oka vaccine has proven to be safe
and effective. For these reasons, there has been significant research into recombinant vaccines
using VZV Oka as a vector for the expression of foreign antigens.
The study presented in this thesis is based on over a decade of research into recombinant
SVV viruses. Two previous studies have tested the hypothesis that recombinant SVV-SIV
vaccines can be used to induce immune responses against SIV (Traina-Dorge et al., 2010; Ou et
al., 2007). Both studies have found that rSVV-SIV vaccines can induce low levels of neutralizing
antibodies to SIV in immunized primates. One of the studies also demonstrated that it can reduce
viral loads following intravenous challenge with pathogenic SIV (Traina-Dorge et al., 2010).
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Recombinant Vaccines
Some of the most successful vaccines that have been developed are live attenuated
vaccines with examples including measles, rubella, and varicella vaccines (Principles of
Vaccination). Live attenuated vaccines produce a very robust immune response and usually only
have to be taken once. While live attenuated vaccines are very effective at inducing the desired
immune response, they also come with risks. In order for live attenuated vaccines to work they
have to replicate in the host. Because the virus is weakened, the vast majority of people who are
immunized will never become symptomatic, but it is possible for some individuals to develop
full blown infections. People with compromised immune systems are at the greatest risk for
developing these infections. For viruses like VZV that are not particularly deadly to children at
the age of vaccination, live attenuated viruses are a justified risk. For viruses that are very deadly
like HIV, live attenuated vaccines carry an unjustifiable risk. Fortunately, advancements in
biochemistry have now enabled researchers to pursue recombinant genomic and recombinant
protein vaccines that avoid the risk of attenuating deadly viruses.
There are many types of recombinant vaccines, but the ones studied in this thesis are
created by the insertion of a viral gene (SIV env and gag) that codes for a specific antigen into
the genome of another virus (SVV). These vaccines work by inducing the host to generate the
foreign antigens coded for in the viral genome without producing infectious virions. Because no
pathogenic virions are produced, these vaccines are much safer than live attenuated vaccines.
Using viral vectors to introduce foreign genetic material has unique advantages when
compared to other recombinant vectors. Because viral vectors infect cells, they induce the
production of foreign antigens within the host cell. By generating the viral antigens
intracellularly, antigens can be processed and loaded onto major histocompatibility complex
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class I molecules on the surface of infected cells, and help facilitate cellular immune responses
(Nascimento & Leite, 2012). The production of both cellular and humoral immunity is important
in the development of vaccines against resilient pathogens such as HIV. Because viral vectors
can induce both types of immunity they are the focus of extensive research regarding HIV
vaccines. One of the most successful HIV vaccine candidates to date was a recombinant
adenovirus expressing three different HIV surface antigens. This vaccine made it to human trials,
however in these trials it was found that the vaccine was not sufficiently protective against HIV
and that it increased the rate of HIV infection in vaccinees that had pre-existing immunity to the
adenovirus vector (Buchbinder et al., 2008).

14

CHAPTER 3: METHODS

Experimental Design
The vaccine used to immunize primates that are analyzed in this thesis is a recombinant
SVV virus expressing the SIV env and gag antigens. The rSVV-SIV virus was created using the
SVV cosmid recombination system (Gray & Mahalingam, 2005). The presence of SIV env and
gag genes in the rSVV-SIV genome was confirmed using PCR. Rhesus macaques from the
Tulane National Primate Research Center were used as the test subjects for this project. The
experimental group was inoculated with the rSVV-SIV env and gag vaccines at 0, 8, 24, 43, and
54 weeks while also receiving SIV gag/env protein vaccines at 24, 43, and 54 weeks. The
subjects were challenged with SIVmac251, a pathogenic macaque strain of SIV, intrarectally
beginning at week 61. This method of challenge was chosen to best replicate real-world
transmission of HIV. Intravenous challenge, while an option, is a much less common route of
transmission so it was not chosen for this study. Sera was collected at regular intervals over the
course of the trial to analyze the immune response. Pre-inoculation sera was also collected to
ensure that none of the monkeys had previously been infected with SIV or SVV.
A heterologous prime boost method was chosen for the immunization protocol in this
study. Prime boosted immunization protocols are a common method used to increase the desired
immune response by using multiple inoculations of a vaccine. Because both a recombinant
vaccine and purified protein vaccines were used in the immunization protocol it is said to be
heterologous. The immunization protocol can be seen in the figure below.
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Figure 2. Immunization Protocol

Indirect ELISA
ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed
for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and
hormones (Overview of ELISA). ELISA assays work by using enzyme linked antibodies to bind
to the target antigen and then adding a substrate that the bound enzyme can interact with to
produce a colored product. The ELISA assays performed for this thesis were indirect ELISA
assays. In indirect ELISA there are two antibodies: a primary antibody and a conjugated
secondary antibody. The primary antibody binds specifically to the target antigen. For this
project the primary antibody was the SVV antibodies found in the monkey’s sera. The secondary
antibody is an antibody that binds to the constant region of the primary antibody and is
conjugated with an enzyme. For this project the secondary antibody was mouse anti-monkey
IgG-HRP (horseradish peroxidase). After sequential incubation with the primary antibody
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followed by the secondary antibody, a substrate is added that the enzyme on the secondary
antibody can react with to produce a colored product.

Figure 3. Indirect ELISA. Immobilized antigen is bound to the sides of the well.
Primary antibody binds to the target antigen while unbound antibody is washed off.
Secondary antibody is added and binds to the constant region of the primary antibody
while unbound secondary antibody is washed off. Substrate is added, converted into
colored product by conjugated enzyme, and the signal is then analyzed (ELISA Assays).

Protocol
SVV infected vero cells were grown in a 175cm confluent flask. The infected cells were
scraped from the sides of the flask using a sterile scraper, spun for 10 minutes at 1500xg, and the
resulting pellet was suspended in 10mL of 1x PBS. The cells were then spun again for 10
minutes at 1500xg and the resulting pellet was suspended in 2mL of 1% triton-X, 0.1M GlycineNaOH buffer. The cells were then incubated on ice for 30 minutes and sonicated in a 2mL
centrifuge tube. The solution was transferred to a round bottom centrifuge tube and spun down at
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41,000xg. This lysate, containing SVV antigens, was then aliquoted and stored at -80°C to be
used during all ELISA assays. To prepare a 96 well plate, a tube of SVV antigen was brought to
room temperature, diluted to a concentration of 5 µg/mL using PBS, and 100µl of the 5 µg/mL
solution was added to each well. This completed the plate preparation.
The day before analyzing sera, the appropriate number of wells on the 96 well plate was
prepared by removing the 100µl of lysate and washing two times with 100µl of phosphate
buffered saline with tween (PBS-T). Next 100µl of blocking buffer was added to each well. The
blocking buffer was made by dissolving 3g of Bovine Serum Albumin and 0.2g Sodium Azide in
100mL of 1xPBS. The blocking solution functions to block non-specific binding of the primary
antibody by adding a generic protein (BSA) to occupy non-specific binding sites. The plate with
blocking buffer was then stored overnight at 4°C. After incubating overnight, the blocking
buffer was removed and each well was washed two times with 100µl PBS-T. The plate and all
reagents were allowed to come to room temperature while serial dilutions of the appropriate
monkey sera were prepared. Once the dilutions were prepared and the reagents were at room
temperature, 100µl of each dilution was loaded onto the plate. Dilutions were loaded from most
dilute to least dilute and allowed to incubate for one hour. After incubation, each well was
emptied and washed three times with 200µl PBS-T. Next, a 1:2000 dilution of the secondary
antibody, mouse anti-monkey IgG HRP-conjugated, was prepared and 100µl was loaded into
each well. The secondary antibody was incubated on the plate for 30 minutes. After incubation,
the secondary antibody was removed and each well was again washed three times with 200µl
PBS-T. Next, 100µl of tetramethylbenzidine, a substrate that the HRP enzyme converts to a blue
product, was loaded into each well and incubated for exactly 20 minutes. At 20 minutes 100µl of
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acid stop solution, a solution that terminated the TMB-HRP reaction by lowering the pH, was
quickly loaded into each well and the plate was analyzed by the plate reader in Shoemaker 209.
Previous studies using positive and negative controls determined that a cutoff value of 0.1
absorbance at 450nm was appropriate for this assay. If absorbance was above 0.1 for a well, the
well was said to be positive; if absorbance was below 0.1 the well was said to be negative. Serial
dilutions of each sera were analyzed with the goal of finding the dilution at which the sera
became negative. The antibody titer was recorded as the reciprocal of the value of the dilution
before the sera became negative.
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CHAPTER 4: SVV ANTIBODY RESPONSE

Results
Sera from each monkey was collected at seven different times: pre-inoculation, 4 weeks
after vaccination one (PV1), 2 weeks after vaccination two (PV2), 2 weeks after vaccination
three (PV3), 2 weeks after vaccination four (PV4), at vaccination five (PV5), and 4 weeks after
testing SIV+. These sera were all run through ELISA assays to measure SVV antibody titers
according to the protocol discussed above. The results for three different monkeys LK56, LK58,
and LK60 are shown in the figures below.
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1-16k
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Table 1. SVV Antibody Titers for LK56, LK58, and LK60
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Figure 5. SVV Antibody Titers as a Function of Time.
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PV5

SIV+4wk

Figure 4 shows the absorbance values for LK60 pre-immune and PV1 sera. This figure
illustrates the method by which absorbance values from indirect ELISA assays were converted
into antibody titers. The antibody titer was recorded as the reciprocal of the greatest dilution that
is above the cutoff value. The pre-immune sera crossed the cutoff value at the 1-500 dilution, so
the antibody titer was recorded as the reciprocal of the previous 1-250 dilution. The PV1 sera
crossed the cutoff value at 1-32k so the antibody titer was recorded as the reciprocal of the
previous 1-16k dilution. The data in Table 1 and Figure 5 was calculated by repeating this
process for the absorbance values from each assay.
The results from Table 1 and Figure 5 show that in all three animals there was a
significant antibody response after the 1st immunization. LK56 saw a 16-fold increase, LK58 saw
an 8-fold increase, and LK 60 saw a 64-fold increase in SVV antibody titer from pre-inoculation
to PV1. After the second vaccination there was another significant increase in SVV antibody
titers. The combination of the rSVV-SIV vaccines and purified SIVenv and SIVgag protein
vaccines given as the third, fourth, and fifth vaccinations were successful in maintaining high
antibody titers throughout the duration of the study.

Discussion
The data presented in this thesis shows that there was a strong humoral response to the
SVV vector used in the rSVV-SIV vaccines. The monkeys from this study were never
challenged with pathogenic strains of SVV, but the high antibody titers against the SVV vector
suggest that the vaccine may be effective at protecting against future SVV infections. Although
the primary goal of these recombinant vaccines is to immunize against SIV not SVV, a thorough
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analysis of the immune response to both the vector and the recombinant SIV genes is important
for future research.
While it was not the focus of this thesis, data on the immune response to SIV in the
immunized monkeys was also collected in this study. The data showed that the immunization
protocol using rSVV-SIV gag/env vaccines with a purified SIV gag/env protein booster was
effective in eliciting a strong antibody and cellular immune response to SIV. After being
challenged multiple times with a pathogenic strain of SIV, 37% of immunized monkeys never
contracted SIV. The 63% of primates that did contract SIV exhibited lower viral loads when
compared to controls. These promising results demonstrate the efficacy of the simian model and
can be used to help guide other studies into recombinant vaccines.
To date all research done using these rSVV-SIV gag/env vaccines has been performed on
monkeys that were naïve to SVV. Future studies could evaluate the immune response to rSVVSIV vaccines in monkeys that had been previously infected with SVV. These studies could
analyze how pre-existing SVV antibodies affect the rSVV-SIV vaccine and its ability to illicit an
immune response. Other future research could focus on the simian model using rSVV-SIV
vaccines, but using different SIV proteins.
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